Abivax (Group)

http://www.abivax.com

ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral drugs and human therapies to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months. ABX464 has been developed using ABIVAX’ anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients’ clear important pathogenic viruses. Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy. ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation. The company is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). *

	Start	2013-12-27 merged
	Today	Abivax S.A. (Euronext Paris: ABVX)
	Industry	therapeutic vaccine
	Industry 2	virostatic agent
	Person	Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD)
	Person 2	Kenny, Daniel (Abivax 201410– COO + VP Business Development before Baxter Vaccines + Baxter BioScience)

	Region	Paris
	Country	France
	Street	5 rue de la Baume
	City	75008 Paris
	Tel	+33-1-5383-0841
		Address record changed: 2017-01-11

Basic data	Employees	B: 11 to 50 (2014-01-01)
	Currency	EUR
	Annual sales	357,000 (income, operating (2017) 2017-12-31)
	Profit	-11,223,000 (2017-12-31)
	Cash	17,032,000 (2017-12-31)

		* Document for ï¿½About Sectionï¿½: Abivax S.A.. (9/15/15). "Press Release: Abivax Appoints Antonino Ligresti, MD and Dominique Costantini, MD to its Board of Directors". Paris.

		Record changed: 2018-09-12

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Abivax (Group)

More documents for Abivax (Group)